Valore202020212022202320242025TTMSpese di vendita, generali e amministrative1.25 B1.2 B1.36 B1.47 B1.54 B1.67 B1.72 BRicerca e sviluppo———————Reddito operativo1.69 B1.8 B1.34 B1.6 B2.09 B2.04 B2.09 BProventi non operativi, Totale16.76 M6.38 M-15.77 M-19.18 M-69.81 M-102.69 M-80.67 MOneri finanziari, al netto degli interessi capitalizzati300.88 M282.32 M351.92 M383.13 M443.18 M539.92 M—Proventi non operativi, esclusi gli oneri finanziari-300.88 M-282.32 M-351.92 M-383.13 M-443.18 M-539.92 M0Entrate/uscite straordinarie16.76 M6.38 M-15.77 M-19.18 M-69.81 M-102.69 M-80.67 MUtile al lordo delle imposte1.32 B1.52 B966.28 M1.18 B1.53 B1.35 B1.4 BQuota di utile26.92 M26.94 M26.52 M27.86 M26.19 M33 M35.73 MImposte313.93 M306.73 M198.09 M220.12 M279.66 M293.11 M305.19 MInteressi di minoranza221.03 M233.31 M221.24 M265.44 M314.39 M331.91 M340.12 MAltri proventi/oneri al netto delle imposte-747 K-11.23 M-21.69 M8.94 M-13.41 M17.55 M17.98 MUtile netto al lordo delle attività cessate783.29 M978.45 M546.95 M691.53 M936.34 M721.8 M781.42 MAttività cessate-9.65 M013.45 M0025 M—Utile netto773.64 M978.45 M560.4 M691.53 M936.34 M746.8 M781.42 MRegolazione della diluizione———————Dividendi privilegiati———————Utile netto diluito attribuibile agli azionisti ordinari773.64 M978.45 M560.4 M691.53 M936.34 M746.8 M781.42 MUtile base per azione (EPS base)6.469.36.037.6211.0210.0610.94Utile diluito per azione (EPS diluito)6.318.95.857.4210.739.8410.71Numero medio di azioni ordinarie in circolazione119.8 M105.23 M92.99 M90.79 M84.99 M74.23 M—Azioni diluite in circolazione122.62 M109.95 M95.83 M93.18 M87.27 M75.89 M—EBITDA2.31 B2.47 B2.06 B2.34 B2.81 B2.75 B—EBIT1.69 B1.8 B1.34 B1.6 B2.09 B2.04 B2.09 BCosto del fatturato———————Altri costi del venduto———————Ammortamento e svalutazione (liquidità)616.63 M667.75 M721.13 M736.47 M716.4 M708.25 M—
DaVita Inc. Common Stock
DaVita Inc., incorporated in Delaware and headquartered in Denver, provides kidney dialysis services through a network of 2,657 outpatient centers in the United States, serving 200,500 patients, and 585 outpatient centers in 14 other countries serving 94,500 patients. The company primarily treats end-stage renal disease, which requires patients to undergo kidney dialysis, often 3 times per week for the rest of their lives unless they receive a kidney transplant via organ donation.
In 2025, 68% of the company's revenues came from Medicare and other government-based health insurance programs. In 2025, 89% of the company's patients were covered by government-based health insurance programs. Commercial payers, which accounted for 32% of revenues in 2025, generate nearly all of the company's profit as they reimburse at a much higher rate than government-based health insurance programs.
The company is ranked 331st on the Fortune 500.